GGHC
RCKT icon

Gilder Gagnon Howe & Co’s Rocket Pharmaceuticals RCKT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,510
Closed -$55.1K – 260
2025
Q2 		$55.1K Buy
+22,510
New +$114K ﹤0.01% 237
2024
Q2 		– Sell
-19,270
Closed -$519K – 270
2024
Q1 		$519K Sell
19,270
-109
-0.6% -$3.1K 0.01% 242
2023
Q4 		$581K Buy
19,379
+475
+3% +$10.5K 0.01% 222
2023
Q3 		$387K Sell
18,904
-4,484
-19% -$81.5K 0.01% 234
2023
Q2 		$465K Sell
23,388
-60
-0.3% -$1.21K 0.01% 250
2023
Q1 		$402K Buy
23,448
+3,299
+16% +$64.6K 0.01% 226
2022
Q4 		$394K Buy
+20,149
New +$371K 0.01% 221
2022
Q3 		– Sell
-29,659
Closed -$408K – 255
2022
Q2 		$408K Buy
+29,659
New +$354K 0.01% 229

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Gilder Gagnon Howe & Co's RCKT Position: Q3 2025 in Review

Gilder Gagnon Howe & Co sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 22,510 shares — an estimated $55.1K sold.

Gilder Gagnon Howe & Co first reported a position in RCKT in Q2 2022 and held it in 8 quarters. The position peaked at $581K in Q4 2023. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Gilder Gagnon Howe & Co reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 22,510 Rocket Pharmaceuticals shares in Q3 2025, an estimated $55.1K.
  • Gilder Gagnon Howe & Co first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Gilder Gagnon Howe & Co's Rocket Pharmaceuticals position peaked at $581K in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2025, filed 14 Nov 2025.